"Based on the available scientific evidence presented to the Council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness," the FEC told Garin in a letter on that day. Sanofi Philippines declined comment on the Philippines government decision. However, Dr Su-Peing Ng, Global Medical Head of Sanofi Pasteur, told Reuters: "We communicated all known benefits and risks of the vaccine to the Philippines government." That's a fact," said Susan Mercado, a former Philippines health department undersecretary and former senior official at the World Health Organization (WHO). It said in a statement last week that a position paper on the dengue vaccine it published in July 2016 did not include a recommendation for countries to introduce it.

Source: Bangkok Post December 11, 2017 05:03 UTC